Fig. 6: NKX6.1 binds directly to the miR-184 promoter. | Cell Death Discovery

Fig. 6: NKX6.1 binds directly to the miR-184 promoter.

From: Reduced miR-184-3p expression protects pancreatic β-cells from lipotoxic and proinflammatory apoptosis in type 2 diabetes via CRTC1 upregulation

Fig. 6

a–c ChIP-qPCR of NKX6.1 binding to the human miR-184 promoter sequence; data are shown as fold change in miR-184 promoter sequence bound by anti-NKX6.1 antibody compared to isotypic IgG negative control (a). ChIP-qPCR of NKX6.1 binding (b) or histone H3 acetylation (AcH3) (c) at the miR-184 promoter, with or without NKX6.1 siRNA and normalised to IgG control; values are shown as fold change in EndoC-βH1 cells transfected with NKX6.1 siRNA compared to scrambled siRNA; statistics using Mann–Whitney U test (n = 4–5 independent experiments). d–f ChIP-qPCR of NKX6.1 binding to the selected sequence of the murine miR-184 promoter; data are shown as fold change of anti-NKX6.1 antibody compared to isotypic negative control IgG (d); statistics using Mann–Whitney U test (n = 4 independent experiments). ChIP-qPCR of NKX6.1 binding (e) or histone H3 acetylation (AcH3) (f) at the murine miR-184 promoter, with or without 100 μM H2O2 treatment in MIN6 cells; values are shown as fold change of 100 μM H2O2 treated samples compared to untreated samples; statistics using Mann–Whitney U test (n = 4 independent experiments).

Back to article page